Cargando…
Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
BACKGROUND: The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765159/ https://www.ncbi.nlm.nih.gov/pubmed/31553709 http://dx.doi.org/10.2478/raon-2019-0038 |
_version_ | 1783454513646010368 |
---|---|
author | Ovcaricek, Tanja Takac, Iztok Matos, Erika |
author_facet | Ovcaricek, Tanja Takac, Iztok Matos, Erika |
author_sort | Ovcaricek, Tanja |
collection | PubMed |
description | BACKGROUND: The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk of recurrence and death from BC. Whether an individual patient will benefit from adjuvant chemotherapy is an important clinical decision. Decisions that rely solely on clinical-pathological factors can often lead to overtreatment. Multigene signatures represent an important progress in optimal selection of high risk patients that might benefit from the addition of chemotherapy to adjuvant endocrine therapy. CONCLUSIONS: Several signatures are already commercially available and also accepted by international guidelines. Oncotype DX and MammaPrint have been most extensively validated and supported by level IA evidence. |
format | Online Article Text |
id | pubmed-6765159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-67651592019-10-15 Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer Ovcaricek, Tanja Takac, Iztok Matos, Erika Radiol Oncol Review BACKGROUND: The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk of recurrence and death from BC. Whether an individual patient will benefit from adjuvant chemotherapy is an important clinical decision. Decisions that rely solely on clinical-pathological factors can often lead to overtreatment. Multigene signatures represent an important progress in optimal selection of high risk patients that might benefit from the addition of chemotherapy to adjuvant endocrine therapy. CONCLUSIONS: Several signatures are already commercially available and also accepted by international guidelines. Oncotype DX and MammaPrint have been most extensively validated and supported by level IA evidence. Sciendo 2019-09-24 /pmc/articles/PMC6765159/ /pubmed/31553709 http://dx.doi.org/10.2478/raon-2019-0038 Text en © 2019 Tanja Ovcaricek, Iztok Takac, Erika Matos, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Review Ovcaricek, Tanja Takac, Iztok Matos, Erika Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title | Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title_full | Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title_fullStr | Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title_full_unstemmed | Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title_short | Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer |
title_sort | multigene expression signatures in early hormone receptor positive her 2 negative breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765159/ https://www.ncbi.nlm.nih.gov/pubmed/31553709 http://dx.doi.org/10.2478/raon-2019-0038 |
work_keys_str_mv | AT ovcaricektanja multigeneexpressionsignaturesinearlyhormonereceptorpositiveher2negativebreastcancer AT takaciztok multigeneexpressionsignaturesinearlyhormonereceptorpositiveher2negativebreastcancer AT matoserika multigeneexpressionsignaturesinearlyhormonereceptorpositiveher2negativebreastcancer |